ES2149203T3 - Peptido t y peptidos asociados destinados para el tratamiento de las inflamaciones, particularmente la esclerosis multiple. - Google Patents

Peptido t y peptidos asociados destinados para el tratamiento de las inflamaciones, particularmente la esclerosis multiple.

Info

Publication number
ES2149203T3
ES2149203T3 ES93907942T ES93907942T ES2149203T3 ES 2149203 T3 ES2149203 T3 ES 2149203T3 ES 93907942 T ES93907942 T ES 93907942T ES 93907942 T ES93907942 T ES 93907942T ES 2149203 T3 ES2149203 T3 ES 2149203T3
Authority
ES
Spain
Prior art keywords
absent
thr
ser
gly
treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES93907942T
Other languages
English (en)
Inventor
Anders Jorgen Andersen
Roger Aston
Peter Louis Carlen
Penelope Reed Doob
Douglas Kevin Macfadden
David James Phipps
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Advanced Immuni T Inc
Original Assignee
Advanced Immuni T Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from DK92645A external-priority patent/DK64592D0/da
Application filed by Advanced Immuni T Inc filed Critical Advanced Immuni T Inc
Application granted granted Critical
Publication of ES2149203T3 publication Critical patent/ES2149203T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1002—Tetrapeptides with the first amino acid being neutral
    • C07K5/1005—Tetrapeptides with the first amino acid being neutral and aliphatic
    • C07K5/1013—Tetrapeptides with the first amino acid being neutral and aliphatic the side chain containing O or S as heteroatoms, e.g. Cys, Ser
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/549—Sugars, nucleosides, nucleotides or nucleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/61—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule the organic macromolecular compound being a polysaccharide or a derivative thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Molecular Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

PEPTIDO T Y SUS ANALOGOS LINEALES O CICLICOS DE LA FORMULA GENERAL (1): I-A-B-C-D-E-F-G-H-II, EN DONDE A ES ALA, GLY, VAL, SER, THR O AUSENTE, B ES ALA, GLY, VAL, SER, THR O AUSENTE; C ES SER, THR O AUSENTE, D ES SER, THR, ASN, GLU, ARG, ILE, LEU O AUSENTE, E ES SER, THR, ASP O AUSENTE, F ES THR, SER, ASN, ARG, GLN, LYS, TRP O AUSENTE, G ES TYR O AUSENTE, H ES THR, ARG, GLY, MET, MET (O), CYS, THR, GLY, O AUSENTE E I ES CYS O AUSENTE, II ES CYS, UN GRUPO AMIDA, GRUPO AMIDA SUSTITUIDO, UN GRUPO ESTER O AUSENTE, ESTANDO AL MENOS UNO DE LOS AMINO ACIDOS OPCIONALMENTE SUSTITUIDO POR UN CARBOHIDRATO POLIMERICO O MONOMERICO O DERIVADOS DE ELLOS, SIENDO REALIZADA TAL SUSTITUCION A TRAVES DE HIDROXILO Y/O AMIDO Y/O GRUPOS AMIDO DE LOS AMINO ACIDOS, QUE COMPRENDEN AL MENOS 4 AMINO ACIDOS, Y SUS SALES FARMACEUTICAMENTE ACEPTABLES, SE USAN EN EL TRATAMIENTO O PREVENCION DE INFLAMACION. EN PARTICULAR, LOS PEPTIDOS SE USAN EN EL TRATAMIENTO O PREVENCION DE ESCLEROSIS MULTIPLE, MIELOPATIAS (INCLUYENDO MIELOPATIA ASOCIADA CON HTLV-1) Y SINTOMAS Y ENFERMEDADES ASOCIADAS CON ACTIVACION INMUNE CRONICA, QUE INCLUYE SINDROME DE FATIGA, CHOQUE TOXICO, ARTRITIS, ENFERMEDAD INFLAMATORIA DEL INTESTINO Y RESPUESTAS ANFITRION CONTRA INJERTO E INJERTO CONTRA ANFITRION EN RECEPTORES DE TRANSPLANTE.
ES93907942T 1992-03-27 1993-03-29 Peptido t y peptidos asociados destinados para el tratamiento de las inflamaciones, particularmente la esclerosis multiple. Expired - Lifetime ES2149203T3 (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US85883292A 1992-03-27 1992-03-27
DK92645A DK64592D0 (da) 1992-05-14 1992-05-14 Peptider til terapeutisk behandling
US91511892A 1992-07-17 1992-07-17
US98767492A 1992-12-09 1992-12-09

Publications (1)

Publication Number Publication Date
ES2149203T3 true ES2149203T3 (es) 2000-11-01

Family

ID=27439352

Family Applications (2)

Application Number Title Priority Date Filing Date
ES99101349T Expired - Lifetime ES2222625T3 (es) 1992-03-27 1993-03-29 Peptido t y peptidos asociados destinados al tratamiento de la inflamacion incluyendo la esclerosis multiple.
ES93907942T Expired - Lifetime ES2149203T3 (es) 1992-03-27 1993-03-29 Peptido t y peptidos asociados destinados para el tratamiento de las inflamaciones, particularmente la esclerosis multiple.

Family Applications Before (1)

Application Number Title Priority Date Filing Date
ES99101349T Expired - Lifetime ES2222625T3 (es) 1992-03-27 1993-03-29 Peptido t y peptidos asociados destinados al tratamiento de la inflamacion incluyendo la esclerosis multiple.

Country Status (12)

Country Link
EP (2) EP0960886B1 (es)
JP (1) JP3520084B2 (es)
KR (1) KR100312300B1 (es)
AT (2) ATE194495T1 (es)
AU (3) AU684713B2 (es)
CA (1) CA2132516A1 (es)
DE (2) DE69333537T2 (es)
DK (2) DK0960886T3 (es)
ES (2) ES2222625T3 (es)
PT (1) PT960886E (es)
UA (1) UA41881C2 (es)
WO (1) WO1993020102A1 (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5739109A (en) * 1988-12-16 1998-04-14 Advanced Immunit Inc. Method of treating neuroinflammatory degenerative diseases
WO1995008338A1 (en) * 1993-09-24 1995-03-30 Peptide Technology Limited Method for the treatment or prevention of eczema/dermatitis
DE69433817T2 (de) * 1993-09-24 2005-07-14 Advanced Immuni T, Inc. Lineare und cyklische peptide zur behandlung oder vorbeugung der crohn'schen krankheit und/oder der ulzerativen kolitis
KR20020063182A (ko) * 1999-11-09 2002-08-01 어드밴스드 임뮤니 티, 인코포래이티드 펩티드 ｔ의 투여를 통해 초기 유전자 발현을변경시킴으로써 바이러스 질환 및 기타 장애를 치료하는방법
JP4611233B2 (ja) * 2005-04-06 2011-01-12 ニッタ株式会社 歩行訓練支援装置
US10501494B2 (en) * 2013-04-26 2019-12-10 Creative Bio-Peptides Uses of peptides to treat brain injury and disease
EP2832373B1 (en) * 2013-08-02 2017-04-12 Experimentelle Pharmakologie & Onkologie Berlin Buch Liposome for blocking site-specifically chemokine-related inflammatory processes in vascular diseases and metastasis

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1987007614A1 (en) * 1986-06-03 1987-12-17 Pert Candace B Small peptides which inhibit binding to t-4 receptors
NZ221440A (en) * 1986-08-20 1991-11-26 Genetic Systems Corp Composition containing monoclonal antibodies/peptides useful in treating and diagnosing hiv infections
AU1808088A (en) * 1987-05-22 1988-12-21 Syntbiotech, Inc. Synthetic peptides and a method of treating aids
US5189022A (en) * 1988-05-27 1993-02-23 The United States Of America As Represented By The Secretary Of Health And Human Services Composition for the treatment of chronic fatigue syndrome
WO1989012067A1 (en) * 1988-05-27 1989-12-14 The United States Of America, As Represented By Th Compositions having use as treatment of psoriasis and neuropsychiatric deficits

Also Published As

Publication number Publication date
AU718442B2 (en) 2000-04-13
EP0635027A1 (en) 1995-01-25
EP0960886B1 (en) 2004-05-26
UA41881C2 (uk) 2001-10-15
ES2222625T3 (es) 2005-02-01
ATE267838T1 (de) 2004-06-15
KR950700931A (ko) 1995-02-20
PT960886E (pt) 2004-10-29
EP0960886A1 (en) 1999-12-01
AU684713B2 (en) 1998-01-08
DE69329023T2 (de) 2001-03-22
AU725680B2 (en) 2000-10-19
DE69333537D1 (de) 2004-07-01
AU3895393A (en) 1993-11-08
CA2132516A1 (en) 1993-10-14
EP0635027B1 (en) 2000-07-12
JP3520084B2 (ja) 2004-04-19
DK0960886T3 (da) 2004-09-27
DE69333537T2 (de) 2005-06-16
JPH07507061A (ja) 1995-08-03
KR100312300B1 (ko) 2002-03-20
AU2254999A (en) 1999-05-20
ATE194495T1 (de) 2000-07-15
WO1993020102A1 (en) 1993-10-14
DK0635027T3 (da) 2000-10-02
AU6354298A (en) 1998-06-18
DE69329023D1 (de) 2000-08-17

Similar Documents

Publication Publication Date Title
Hamamoto et al. Antimicrobial activity and stability to proteolysis of small linear cationic peptides with D‐amino acid substitutions
SE9100799L (sv) Rekombinant derivat av human faktor viii
ATE108662T1 (de) Antimikrobielle peptide, zusammensetzungen, die diese enthalten, und verwendungen daraus.
DK0711305T3 (da) Protegriner
CA2234409A1 (en) Transferrin receptor protein of moraxella
KR900002801A (ko) 당뇨병 치료용 약학적제제
ATE171712T1 (de) Neuartiger menschlicher proteaseinhibitor vom kunitz-typ und entsprechende varianten
WO1999006440A8 (en) Novel synthetic peptides with antimicrobial and endotoxin neutralizing properties for management of the sepsis syndrome
ES2149203T3 (es) Peptido t y peptidos asociados destinados para el tratamiento de las inflamaciones, particularmente la esclerosis multiple.
ES2070635T3 (es) Peptidos para tratamiento.
ATE287963T1 (de) Pseudomonas exotoxin - myelin basisches protein chimäre proteine
Miyasaki et al. Sensitivity of periodontal pathogens to the bactericidal activity of synthetic protegrins, antibiotic peptides derived from porcine leukocytes
RU94027578A (ru) Фармацевтическая композиция и способ лечения рассеянного склероза
KR950702573A (ko) 공유결합된 항산화제를 갖는 합성 펩티드 폐 계면활성제(Synthetic Peptide Lung Surfactants Having Covalently Bonded Antioxidants)
ATE221084T1 (de) Neuer megakaryocyten-verstärker
US6573242B1 (en) Dihydroxypropyl cysteine peptide and agent containing this peptide
KR950702574A (ko) 펩티드 폐 계면활성제 및 치료용 혼합물(Peptide Lung Surfactants and Therapeutic Combinations)
RU94046096A (ru) Линейные или циклические пептиды, их применение, способы лечения и конъюгаты пептидов
ATE308617T1 (de) Rantes mutanten und deren therapeutischen anwendungen
DE68905097D1 (de) Peptid-molekuele, wirksam gegen gram-positive keime.
ATE425988T1 (de) Peptide mit affinitat fur ein phospholipid und deren verwendung
RU94036770A (ru) Домен ингибитора протеазы, днк, вектор, клетка, способ получения домена, фармацевтическая композиция, применение домена

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 635027

Country of ref document: ES